睿知中国医院研究地图
候选清单

正在招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 21 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 21

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心西南医科大学附属医院Affiliated Hospital of Southwest Medical University泸州医院页面
  2. 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
  3. 研究中心皖南医科大学第一附属医院First Affiliated Hospital of Wannan Medical College芜湖医院页面
  4. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  5. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  6. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  7. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  8. 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
  9. 研究中心甘肃省肿瘤医院Gansu Provincial Cancer Hospital兰州医院页面
  10. 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
  11. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  12. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  13. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  14. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  15. 研究中心江西省肿瘤医院Jiangxi Cancer Hospital南昌医院页面
  16. 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
  17. 研究中心大连医科大学附属第二医院Second Hospital of Dalian Medical University大连医院页面
  18. 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
  19. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  20. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  21. 研究中心武汉大学中南医院Zhongnan Hospital of Wuhan University武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06854445,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histological or cytological diagnosis of diffuse large B-cell lymphoma in accordance with the World Health Organization (WHO) diagnostic criteria in 2022;

    入选标准第 5 条

    Pathological diagnosis results containing CD20 positive expression and Myc rearrangement negative after anti-CD20 treatment must be provided;

    入选标准第 6 条

  3. Subjects with relapsed or refractory diffuse large B-cell lymphoma who have received at least 1 line of systemic therapy;

    入选标准第 7 条

    Failure to recover from adverse reactions to Common Terminology Criteria for Adverse Events version 5.0 (CTCAEv5.0) criteria ≤ grade 1 from previous treatment;

    排除标准第 3 条

    previous use of other antibody drugs targeting CD3 and CD20 at the same time;

    排除标准第 5 条

    received Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy, or other immune cell therapy, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months before the first dose;

    排除标准第 6 条

    received chemotherapy, immunotherapy, monoclonal antibody therapy 4 times before the first dose, 2 times received radiotherapy or small molecule targeted drugs, or subjects who are still within 5 half-lives of the drug, the washout period is calculated from the end time of treatment;

    排除标准第 8 条

    received treatment with Chinese patent medicines with clear anti-tumor indications in the package insert of National Medical Products Administration (NMPA)-approved drugs 2 times before the first dose;

    排除标准第 9 条

  4. Eastern Cooperative Oncology Group (ECOG) score 0 \~ 2 points;

    入选标准第 3 条

  5. According to the Lugano criteria in 2014, there is at least one measurable lesion, that is, the long diameter of lymph node lesions > 15 mm or extranodal lesions > 10 mm according to CT cross-sectional images; Positron emission tomography - computerized tomography (PET-CT) scan shows PET positive;

    入选标准第 9 条

  6. Subjects who had or currently had other malignant tumors within 5 years prior to the first dose;

    排除标准第 1 条

    History of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency diseases;

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06854445,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The subjects voluntarily participate in this study, sign the informed consent form, and have good compliance;
  2. Age ≥18 years (calculated from the date of informed consent);
  3. Eastern Cooperative Oncology Group (ECOG) score 0 \~ 2 points;
  4. Expected survival greater than 12 weeks;
  5. Histological or cytological diagnosis of diffuse large B-cell lymphoma in accordance with the World Health Organization (WHO) diagnostic criteria in 2022;
  6. Pathological diagnosis results containing CD20 positive expression and Myc rearrangement negative after anti-CD20 treatment must be provided;
  7. Subjects with relapsed or refractory diffuse large B-cell lymphoma who have received at least 1 line of systemic therapy;
  8. Not suitable for hematopoietic stem cell transplantation;
  9. According to the Lugano criteria in 2014, there is at least one measurable lesion, that is, the long diameter of lymph node lesions > 15 mm or extranodal lesions > 10 mm according to CT cross-sectional images; Positron emission tomography - computerized tomography (PET-CT) scan shows PET positive;
  10. Laboratory tests meet specific criteria;
  11. Adopt effective contraceptive measures;

排除标准:Exclusion Criteria:

  1. Subjects who had or currently had other malignant tumors within 5 years prior to the first dose;
  2. Previous or current involvement or suspected involvement of the central nervous system by lymphoma;
  3. Failure to recover from adverse reactions to Common Terminology Criteria for Adverse Events version 5.0 (CTCAEv5.0) criteria ≤ grade 1 from previous treatment;
  4. History of previous anti-tumor treatment:
  5. previous use of other antibody drugs targeting CD3 and CD20 at the same time;
  6. received Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy, or other immune cell therapy, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months before the first dose;
  7. previous treatment with R-GemOx or GemOx;
  8. received chemotherapy, immunotherapy, monoclonal antibody therapy 4 times before the first dose, 2 times received radiotherapy or small molecule targeted drugs, or subjects who are still within 5 half-lives of the drug, the washout period is calculated from the end time of treatment;
  9. received treatment with Chinese patent medicines with clear anti-tumor indications in the package insert of National Medical Products Administration (NMPA)-approved drugs 2 times before the first dose;
  10. Subjects who have undergone major surgical treatment, significant traumatic injury, or expected major surgery during the study treatment period within 4 weeks prior to the first use of medication, or have long-term untreated wounds or fractures;
  11. Subjects who experience any bleeding or bleeding events ≥ Common Terminology Criteria Adverse Event (CTC AE) grade 3 within 4 weeks prior to the first administration;
  12. Hyperactive/venous thrombotic events within 6 months prior to first dose,Such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism or any other history of severe thromboembolism;
  13. Clinically significant uncontrolled pleural effusion, ascites and more than moderate pericardial effusion requiring repeated drainage;
  14. Decompensated cirrhosis (Child-Pugh class B or C liver function) and active hepatitis;
  15. Pulmonary disease, including any of the following: 1) with or without current pneumonitis requiring corticosteroid therapy; 2) with or suspected chronic obstructive pulmonary disease (COPD), and forced expiratory volume in 1 second (FEV1) < 60% (predicted);
  16. Brain or mental disorders;
  17. Have major cardiovascular disease;
  18. Active or uncontrolled infection (≥ CTCAE grade 2 infection), including bacterial, fungal or viral infections including but not limited to active pneumonia, syphilis and tuberculosis.
  19. Unexplained fever > 38.5℃ during screening or before the first dose;
  20. Renal failure requiring hemodialysis or peritoneal dialysis, previous history of nephrotic syndrome;
  21. History of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency diseases;
  22. Have or have had prior autoimmune disease requiring treatment.
  23. Prepare to undergo or have previously received organ transplantation, or have a significant host transplant response, or have previously received allogeneic hematopoietic stem cell transplantation; 19、Need to receive systemic immunosuppressive therapy;
  24. Known or suspected history of hemophagocytic syndrome (HLH);
  25. Known hypersensitivity to excipient components of the study drug.
  26. Subjects who participated in other anti-tumor clinical trials within 4 or 5 half-lives before the first dose.
  27. Any condition that, in the judgment of the investigator, would jeopardize the safety of the subject or prevent the subject from completing the study.

引自 ClinicalTrials.gov, NCT06854445, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06854445,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06854445